A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Admin of 5.0g Idarucizumab in Patients Treated with Dabigatran Etexilate who have Uncontrolled Bleeding or require Emergency...